---
id: fluoroquinolones-generations-spectrum_178
category: antimicrobials
tags: [fluoroquinolones, quinolones, generations, spectrum, ciprofloxacin, levofloxacin, moxifloxacin]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## Fluoroquinolones - Generations & Spectrum

**Q:** How are fluoroquinolones classified by generation, and what is the evolving antimicrobial spectrum across generations with key organisms covered?

**A:**

## MECHANISM OF ACTION

**Mnemonic: "DNA-GYRASE-TOPOISOMERASE-IV"**

**Fluoroquinolones = inhibit bacterial DNA synthesis:**

**Targets:**
1. **DNA gyrase (topoisomerase II):**
   - **Function:** Supercoiling of DNA (relaxes positive supercoils)
   - **Primary target in gram-negatives**
2. **Topoisomerase IV:**
   - **Function:** Separates daughter DNA strands during replication
   - **Primary target in gram-positives**

**Effect:** **Bactericidal** (inhibit DNA replication → cell death)

**Key Point:** **DNA gyrase = gram-negatives** | **Topoisomerase IV = gram-positives**

---

## FLUOROQUINOLONE GENERATIONS

**Mnemonic: "1-UTI-ONLY | 2-CIPRO-PSEUDO | 3-RESPIRATORY | 4-ANAEROBIC"**

---

## FIRST GENERATION (Historical - Rarely Used)

**Agent:** Nalidixic acid

**Spectrum:**
- **Gram-negatives ONLY** (E. coli, Proteus, Klebsiella)
- **NO Pseudomonas** coverage
- **NO gram-positive** coverage

**Use:** **Urinary tract infections ONLY** (urine concentrations adequate)

**Key Point:** **First generation = UTI only** (historical, rarely used)

---

## SECOND GENERATION (Ciprofloxacin, Ofloxacin, Levofloxacin)

**Mnemonic: "CIPRO-LEVO-OFLOX"**

### **CIPROFLOXACIN (Prototype):**

**Spectrum:**

**Gram-Negatives (EXCELLENT):**
- ***Pseudomonas aeruginosa*** (BEST oral anti-pseudomonal - 70-80% susceptible)
- **Enterobacterales** (E. coli, Klebsiella, Proteus, Enterobacter - BUT increasing resistance)
- **Haemophilus influenzae**
- **Moraxella catarrhalis**
- **Neisseria species** (gonorrhea, meningitidis - BUT increasing resistance to gonococcus)
- ***Salmonella, Shigella, Campylobacter*** (enteric pathogens)
- ***Francisella tularensis*** (tularemia - alternative to doxycycline)
- ***Yersinia pestis*** (plague - alternative to streptomycin)
- ***Burkholderia pseudomallei*** (melioidosis)

**Atypical Bacteria:**
- **Mycobacterium avium complex (MAC)** - part of combination therapy

**Gram-Positives (POOR):**
- ***Staphylococcus aureus*** (MSSA) - MODERATE activity (NOT first-line)
- **MRSA** - NO reliable activity
- **Streptococcus pneumoniae** - POOR activity (NOT reliable)
- **Streptococcus pyogenes (GAS)** - POOR activity

**Anaerobes:**
- **NO activity**

**Key Point:** **Cipro = BEST oral anti-pseudomonal** | **POOR gram-positive/anaerobe coverage**

---

### **LEVOFLOXACIN:**

**Spectrum:**
- **Similar to ciprofloxacin** for gram-negatives (but slightly LESS active vs Pseudomonas)
- **IMPROVED gram-positive activity** vs ciprofloxacin:
  - **Streptococcus pneumoniae** (90-95% susceptible - MUCH better than cipro)
  - ***Staphylococcus aureus*** (MSSA) - good activity
- **NO anaerobic activity**

**Key Point:** **Levofloxacin = better gram-positive than cipro** | **Respiratory fluoroquinolone**

---

### **OFLOXACIN:**

**Spectrum:**
- **Similar to ciprofloxacin** (less commonly used)
- **Ophthalmic formulation** (eye drops for conjunctivitis)

**Key Point:** **Ofloxacin = less commonly used** | **Ophthalmic formulation available**

---

## THIRD GENERATION (Levofloxacin - High Dose)

**Levofloxacin 750mg:**
- **"Respiratory fluoroquinolone"** (high-dose formulation)
- **Enhanced gram-positive coverage** (S. pneumoniae including some resistant strains)
- **Use:** Community-acquired pneumonia (CAP)

**Key Point:** **Levofloxacin 750mg = respiratory fluoroquinolone** (CAP coverage)

---

## FOURTH GENERATION (Moxifloxacin, Delafloxacin)

**Mnemonic: "MOXI-ANAEROBIC-ATYPICAL"**

### **MOXIFLOXACIN:**

**Spectrum:**

**Gram-Positives (ENHANCED):**
- **Streptococcus pneumoniae** (excellent - including some resistant strains)
- ***Staphylococcus aureus*** (MSSA) - excellent

**Gram-Negatives (GOOD - BUT LESS than ciprofloxacin):**
- **Enterobacterales** (E. coli, Klebsiella) - good
- ***NO Pseudomonas aeruginosa*** (LOST anti-pseudomonal activity)

**Anaerobes (NEW):**
- **Bacteroides fragilis** (good activity - UNIQUE among fluoroquinolones)
- **Peptostreptococcus**
- **Prevotella**

**Atypical Bacteria (EXCELLENT):**
- ***Mycoplasma pneumoniae***
- ***Chlamydia pneumoniae***
- ***Legionella pneumophila***

**Key Point:** **Moxifloxacin = ANAEROBIC coverage** (unique) | **NO Pseudomonas** | **Best for CAP + atypicals**

---

### **DELAFLOXACIN:**

**Spectrum:**
- **Enhanced gram-positive activity:**
  - ***MRSA*** (excellent - FDA-approved for ABSSSI)
  - **MSSA**
- **Gram-negatives** (similar to ciprofloxacin - including Pseudomonas)
- **Some anaerobic activity** (similar to moxifloxacin)

**Unique Feature:** **Active in acidic environments** (e.g., abscesses - pH 5.5-6)

**Key Point:** **Delafloxacin = MRSA coverage** (FDA-approved for skin infections) | **Active in acidic abscesses**

---

## SPECTRUM COMPARISON TABLE

| **Generation** | **Agent** | **Pseudomonas** | **Gram-Positives** | **Anaerobes** | **Primary Use** |
|----------------|-----------|-----------------|-------------------|---------------|-----------------|
| **1st** | Nalidixic acid | ❌ | ❌ | ❌ | UTI only (historical) |
| **2nd** | Ciprofloxacin | ✅✅ (BEST) | ❌ (poor) | ❌ | UTI, Pseudomonas, GI infections |
| **2nd** | Levofloxacin | ✅ (good) | ✅ (good) | ❌ | CAP, UTI, skin/soft tissue |
| **3rd** | Levofloxacin 750mg | ✅ (good) | ✅✅ (enhanced) | ❌ | CAP (respiratory) |
| **4th** | Moxifloxacin | ❌ | ✅✅ (excellent) | ✅ (unique) | CAP + atypicals, intraabdominal |
| **4th** | Delafloxacin | ✅✅ (excellent) | ✅✅ (MRSA) | ✅ (some) | ABSSSI (MRSA coverage) |

**Key Point:** **Cipro = best Pseudomonas** | **Moxi = anaerobes + atypicals, NO Pseudomonas** | **Delafloxacin = MRSA**

---

## CLINICAL USES BY GENERATION

**Mnemonic: "CIPRO-UTI-PSEUDO | LEVO-CAP | MOXI-ANAEROBIC"**

### **CIPROFLOXACIN:**

**Top Uses:**
1. **Urinary tract infections** (E. coli, Proteus, Klebsiella - BUT increasing resistance)
2. **Pseudomonas aeruginosa infections** (BEST oral option)
3. **Enteric fever** (Salmonella typhi - alternative to ceftriaxone)
4. **Traveler's diarrhea** (Campylobacter, Shigella, Salmonella - BUT increasing resistance)
5. **Prostatitis** (gram-negatives - excellent prostatic penetration)
6. **Anthrax** (post-exposure prophylaxis, treatment)
7. **Plague** (Yersinia pestis - alternative to streptomycin)
8. **Tularemia** (Francisella tularensis - alternative to doxycycline)

**Key Point:** **Cipro = UTI, Pseudomonas, enteric pathogens**

---

### **LEVOFLOXACIN:**

**Top Uses:**
1. **Community-acquired pneumonia** (S. pneumoniae, H. influenzae, atypicals)
2. **Acute bacterial sinusitis** (S. pneumoniae, H. influenzae)
3. **Acute exacerbation of chronic bronchitis** (AECB)
4. **Urinary tract infections** (E. coli, Klebsiella)
5. **Skin and soft tissue infections** (MSSA)

**Key Point:** **Levofloxacin = CAP, sinusitis, UTI**

---

### **MOXIFLOXACIN:**

**Top Uses:**
1. **Community-acquired pneumonia** (S. pneumoniae, atypicals, anaerobes)
2. **Intraabdominal infections** (anaerobic coverage - part of combination therapy)
3. **Complicated skin infections** (MSSA, anaerobes)
4. **Acute bacterial sinusitis** (S. pneumoniae, H. influenzae, anaerobes)
5. **Mycobacterium tuberculosis** (alternative in drug-resistant TB)

**Key Point:** **Moxifloxacin = CAP with atypicals, intraabdominal (anaerobes)**

---

### **DELAFLOXACIN:**

**Top Uses:**
1. **Acute bacterial skin and skin structure infections (ABSSSI)** - FDA-approved for MRSA

**Key Point:** **Delafloxacin = MRSA skin infections**

---

## RESISTANCE MECHANISMS

**Mnemonic: "MUTATIONS-EFFLUX-QNRA"**

**Mechanisms:**
1. **Chromosomal mutations:**
   - **GyrA/GyrB** (DNA gyrase)
   - **ParC/ParE** (topoisomerase IV)
   - **Stepwise accumulation** → high-level resistance
2. **Efflux pumps** (pump drug out of cell)
3. **Plasmid-mediated resistance (qnr genes):**
   - **qnrA, qnrB, qnrS** (protect DNA gyrase/topoisomerase IV from quinolone binding)
   - **AAC(6')-Ib-cr** (aminoglycoside acetyltransferase variant - modifies quinolones)

**Key Point:** **Resistance = chromosomal mutations** (stepwise) | **Plasmid-mediated (qnr genes)**

---

## FLUOROQUINOLONE RESISTANCE PATTERNS

**Increasing Resistance:**
- ***E. coli*** (UTI isolates - 20-30% resistant to ciprofloxacin in many regions)
- ***Neisseria gonorrhoeae*** (>50% resistance - NO LONGER recommended for gonorrhea)
- ***Salmonella typhi*** (increasing resistance in South Asia)
- ***Campylobacter jejuni*** (>50% resistance - avoid empiric use)
- ***Pseudomonas aeruginosa*** (30-40% resistance in many ICU settings)

**Key Point:** **E. coli, gonorrhea, Campylobacter = increasing resistance** (avoid empiric use)

---

**Clinical Pearls:**
- **DNA gyrase = gram-negatives** | **Topoisomerase IV = gram-positives**
- **Cipro = BEST oral anti-pseudomonal** (70-80% susceptible) | **POOR gram-positive coverage**
- **Levofloxacin = better gram-positive than cipro** | **Respiratory fluoroquinolone (750mg)**
- **Moxifloxacin = ANAEROBIC coverage** (unique) | **NO Pseudomonas** | **Best for CAP + atypicals**
- **Delafloxacin = MRSA coverage** (FDA-approved for ABSSSI) | **Active in acidic abscesses**
- **Cipro = UTI, Pseudomonas, enteric pathogens**
- **Levofloxacin = CAP, sinusitis, UTI**
- **Moxifloxacin = CAP with atypicals, intraabdominal (anaerobes)**
- **E. coli, gonorrhea, Campylobacter = increasing resistance** (avoid empiric use)
- **Resistance = chromosomal mutations** (stepwise accumulation)

**Media:**

**Additional Resources:**
- **Sanford Guide:** Fluoroquinolone spectrum
- **IDSA Guidelines:** CAP treatment
- **CDC:** Fluoroquinolone resistance patterns

**Sources:** [Sanford Guide], [IDSA CAP Guidelines], [CDC Resistance Data]
